secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001104659-25-072708
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix SGX945 Phase 2a: 40% improvement in Behçet's ulcers, matching Otezla's 37%
--------------------------------------------------------------------------------

- SGX945 achieved 40% improvement vs placebo on primary endpoint at Week 4; apremilast (Otezla) had 37% improvement.
- 7 of 8 patients reported benefit; 1 patient's skin ulcer resolved; no treatment-related adverse events.
- Improvement sustained at Week 8 (32%) despite stopping treatment at Week 4; Otezla continuous dosing had 41%.
- Company plans reformulation for home subcutaneous injection and a placebo-controlled Phase 2 study.
- Behçet's Disease affects ~18,000 in US; SGX945 well-tolerated with no GI side effects vs Otezla.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000110465925072708/0001104659-25-072708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000110465925072708/tm2522246d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer